Abstract
Neoadjuvant chemotherapy is also included in the treatment of less advanced, operable tumors with unfavorable biological characteristics. However, its wider use opens up new questions regarding postoperative radiotherapy.
The most debatable is the indication for radiotherapy in women who achieve pathological complete remission after neoadjuvant chemotherapy. On the one hand, they have a better prognosis, on the other hand, skipping radiotherapy can lead to a greater rate of locoregional recurrences.
The indication for radiotherapy is therefore still based on preoperative classification and data from retrospective studies. Since radiotherapy can be burdened with late irreversible side effects, the effort is to better identify the patients who will benefit the most from it.
Prospective studies are leading to this, the conclusions of which we still have to wait for.